$SELLAS Life Sciences Group Inc.(SLS)$ It's July, and we're still waiting for the 80th event.
Most people see a delay. I see what happens when an immunotherapy keeps patients alive long enough that events stop occurring on schedule.
GPS isn't CAR-T. It doesn't engineer cells—it trains your own immune system to recognize WT1 and keeps expanding T-cell responses over time. That's exactly why the FDA approved unlimited dosing in REGAL.
No 80th event. Unlimited dosing. Growing immunotherapy spotlight. Change-in-control filings.
The pieces keep lining up. If patients weren't living longer, this trial would've been over months ago.
The delay isn't the story... the data is.
Comments